Osteosarcoma Cell Models for Research

Osteosarcoma is the most common primary malignant bone tumor, with an annual incidence of approximately 3-4 cases per million worldwide (WHO, 2020). It primarily affects adolescents and young adults, with a second peak in the elderly. The 5-year survival rate for localized osteosarcoma is about 60-70% (NCI), but for metastatic or recurrent disease, it drops to less than 20%. Despite aggressive chemotherapy and surgery, outcomes have not improved significantly in decades, highlighting the need for novel therapeutic strategies.

Osteosarcoma is characterized by high genomic complexity, including numerous copy number alterations and structural variants. This makes it an excellent model for studying chromosomal instability and its role in tumorigenesis. Public datasets such as TCGA and TARGET provide extensive genomic and transcriptomic data, enabling integrative analyses. Key open questions include the identification of driver genes amidst the genomic noise, the role of the tumor microenvironment, and mechanisms of drug resistance. Gene-edited cell models are essential tools to functionally validate candidate genes and pathways.

Osteosarcoma pathogenesis involves disruption of several key pathways:

1. TP53 pathway: The TP53 tumor suppressor is mutated in about 20-30% of osteosarcomas, and its pathway is disrupted in nearly all cases. Loss of p53 function leads to genomic instability and evasion of apoptosis.

2. RB1 pathway: The RB1 gene is frequently deleted or inactivated, leading to uncontrolled cell cycle progression. RB1 loss is present in up to 30% of cases.

3. PI3K/AKT/mTOR pathway: This pathway is often activated due to mutations in PIK3CA or loss of PTEN, promoting cell survival and proliferation.

4. Wnt/β-catenin signaling: Aberrant activation of this pathway contributes to osteosarcoma development and metastasis.

Data derived from TCGA and COSMIC databases.

Osteosarcoma cells exhibit deregulation of multiple signaling networks:

• • Wnt/β-catenin: Overactivation leads to increased cell proliferation and invasion. Key components include β-catenin, APC, and GSK3β.
• • MAPK/ERK: Mutations in RAS or RAF genes (e.g., KRAS, BRAF) are rare but can activate this pathway, promoting cell division.
• • PI3K/AKT/mTOR: Activation via PTEN loss or PIK3CA mutations enhances cell survival and metabolism.
• • Notch signaling: Dysregulation contributes to cancer stem cell properties and drug resistance.
• • Hedgehog signaling: Aberrant activation may play a role in osteosarcoma progression.

Common osteosarcoma cell lines include:

Organoids derived from patient tumors are emerging as more physiologically relevant models, preserving tumor heterogeneity and microenvironment interactions.

• • Patient-derived xenografts (PDX): Tumor fragments implanted into immunodeficient mice, preserving original tumor characteristics.
• • Genetically engineered mouse models (GEMM): Conditional knockout of TP53 and RB1 in osteoblast precursors leads to osteosarcoma development.
• • Induced models: Injection of osteosarcoma cell lines into mice to form tumors, useful for studying metastasis and drug response.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. For osteosarcoma, commonly used models include:

• • TP53 knockout lines: Generated in TP53 wild-type cell lines like U2OS or MG-63 to study loss-of-function effects.
• • TP53 R175H knock-in lines: Introduction of a hotspot mutation to study gain-of-function effects.
• • RB1 knockout lines: In cell lines with intact RB1 to assess its tumor suppressor role.
• • MYC overexpression lines: To study oncogenic addiction.

These gene-edited models are commercially available from various providers, ensuring sequence verification and quality control. They are essential for functional validation and drug development.

Gene-edited cell lines allow researchers to determine the functional impact of specific genetic alterations. For example, knocking out TP53 in U2OS cells leads to increased proliferation and resistance to apoptosis, confirming its tumor suppressor role. Similarly, introducing an oncogenic KRAS mutation into HOS cells enhances invasiveness, validating its driver function.

Isogenic cell line pairs (e.g., TP53 wild-type vs. knockout) are used in high-throughput drug screens to identify compounds that selectively kill cancer cells with specific mutations. This approach can also model acquired resistance by exposing cells to increasing drug concentrations and identifying genetic changes that confer resistance.

CRISPR-based synthetic lethality screens can identify genes that are essential only in the presence of a specific mutation. For example, in TP53-null osteosarcoma cells, knocking out certain DNA repair genes may cause cell death, revealing potential therapeutic targets and biomarkers.